Theravance Inc: Premium Company Profile

Introduction

Theravance is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule medicines for the treatment of diseases including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Of its five programs in development, two are in late stage, its telavancin program focusing on treating serious Gram-positive bacterial infections with Astellas and its Beyond Advair collaboration with GSK. The company’s total revenues increased at a CAGR of 235% during 2002-2006, from $0.1 million to $20 million. This represents an absolute total growth of $19 million during the historical period. License, collaboration and other revenues including milestone and upfront payments contributed all of the company’s revenues. Theravance’s total revenues are estimated to increase at a CAGR of 71% between 2006 and 2010, from $20 million to $168 million. Royalties on telavancin sales will be the major contributor to the company’s total growth out to 2010.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization .

Report Highlights

[Studien Infos ausblenden]